BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rossi SA, de Oliveira HC, Agreda-Mellon D, Lucio J, Mendes-Giannini MJS, García-Cambero JP, Zaragoza O. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and Candida spp. Antimicrob Agents Chemother 2020;64:e01921-19. [PMID: 31988099 DOI: 10.1128/AAC.01921-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Iyer KR, Revie NM, Fu C, Robbins N, Cowen LE. Treatment strategies for cryptococcal infection: challenges, advances and future outlook. Nat Rev Microbiol 2021;19:454-66. [PMID: 33558691 DOI: 10.1038/s41579-021-00511-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
2 Kim JH, Cheng LW, Chan KL, Tam CC, Mahoney N, Friedman M, Shilman MM, Land KM. Antifungal Drug Repurposing. Antibiotics (Basel) 2020;9:E812. [PMID: 33203147 DOI: 10.3390/antibiotics9110812] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Spadari CC, Wirth F, Lopes LB, Ishida K. New Approaches for Cryptococcosis Treatment. Microorganisms 2020;8:E613. [PMID: 32340403 DOI: 10.3390/microorganisms8040613] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
4 de Oliveira HC, Rodrigues ML. Repurposing benzimidazoles to fight Cryptococcus. Fungal Biology Reviews 2021;37:27-40. [DOI: 10.1016/j.fbr.2021.04.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jampilek J. Novel avenues for identification of new antifungal drugs and current challenges. Expert Opin Drug Discov 2022. [PMID: 35787715 DOI: 10.1080/17460441.2022.2097659] [Reference Citation Analysis]
6 Musavinasab-Mobarakeh SA, Shams-Ghahfarokhi M, Razzaghi-Abyaneh M. Effect of Allium cepa on LAC1 gene expression and physiological activities in Cryptococcus neoformans. Curr Med Mycol 2021;7:38-43. [PMID: 34553096 DOI: 10.18502/cmm.7.1.6241] [Reference Citation Analysis]
7 Peyclit L, Yousfi H, Rolain JM, Bittar F. Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi. Pharmaceuticals (Basel) 2021;14:488. [PMID: 34065420 DOI: 10.3390/ph14050488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ndugire W, Raviranga NGH, Lao J, Ramström O, Yan M. Gold Nanoclusters as Nanoantibiotic Auranofin Analogues. Adv Healthc Mater 2022;11:e2101032. [PMID: 34350709 DOI: 10.1002/adhm.202101032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Argüelles A, Sánchez-Fresneda R, Martínez-Mármol E, Lozano JA, Solano F, Argüelles JC. A Specific Mixture of Propolis and Carnosic Acid Triggers a Strong Fungicidal Action against Cryptococcus neoformans. Antibiotics (Basel) 2021;10:1395. [PMID: 34827333 DOI: 10.3390/antibiotics10111395] [Reference Citation Analysis]
10 de Oliveira HC, Joffe LS, Simon KS, Castelli RF, Reis FCG, Bryan AM, Borges BS, Medeiros LCS, Bocca AL, Del Poeta M, Rodrigues ML. Fenbendazole Controls In Vitro Growth, Virulence Potential, and Animal Infection in the Cryptococcus Model. Antimicrob Agents Chemother 2020;64:e00286-20. [PMID: 32253211 DOI: 10.1128/AAC.00286-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]